Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Shain Shares Strategies in Newly Diagnosed Myeloma

September 13th 2018

Kenneth H. Shain, MD, PhD, discusses the evolution of treatment for patients with newly diagnosed multiple myeloma and how physicians are leveraging data with chimeric antigen receptor T-cell therapy and minimal residual disease negativity to improve outcomes.

Dr. Raje Discusses the Impact of bb2121in Myeloma

September 12th 2018

Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, discusses the impact of bb2121 in myeloma.

Baz Highlights Emerging Regimens in Relapsed/Refractory Myeloma

September 7th 2018

Rachid Baz, MD, discusses the ARROW, ELOQUENT-3, and OPTIMISMM studies and highlights others that are demonstrating equally impressive response rates in patients with relapsed/refractory multiple myeloma.

Stem Cell Transplantation Feasible in Elderly Patients With Myeloma

September 7th 2018

Andrew L. Pecora, MD, discusses the use of autologous stem cell transplantation in patients aged ≥75 years and the future of care in multiple myeloma.

KRd Regimen Shows Promise in Newly Diagnosed Myeloma

September 6th 2018

Francesca Gay, MD, PhD, discusses the FORTE trial comparing carfilzomib plus lenalidomide and dexamethasone versus carfilzomib plus cyclophosphamide and dexamethasone in newly diagnosed patients with multiple myeloma.

Dr. Baz on Selinexor in Multiple Myeloma

September 5th 2018

Rachid Baz, MD, associate member, head of the Myeloma Section at Moffitt Cancer Center, discusses the potential use of selinexor (KPT-330) in patients with multiple myeloma.

Dr. Shain Discusses Novel Agents in Multiple Myeloma

August 31st 2018

Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses novel agents in multiple myeloma.

Daratumumab/VMP Combo Approved in EU for Frontline Myeloma

August 31st 2018

The European Commission has approved daratumumab for use in combination with bortezomib, melphalan, and prednisone (VMP) for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Venetoclax Triplet Shows Promise in Relapsed/Refractory Multiple Myeloma

August 31st 2018

Luciano J. Costa, MD, PhD, discusses the emerging potential of combing venetoclax with carfilzomib and dexamethasone as a treatment for patients with relapsed/refractory multiple myeloma.

Dr. Munshi on the Role of Checkpoint Inhibitors in Myeloma

August 29th 2018

Nikhil C. Munshi, MD, director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the role of checkpoint inhibitors in myeloma.

Dr. Ostertag on Emerging CAR T Product for Myeloma

August 29th 2018

Eric M. Ostertag, MD, PhD, chief executive officer, Poseida Therapeutics, Inc., discusses an emerging CAR T stem cell memory product for patients with relapsed/refractory multiple myeloma.

FDA Approval Sought for Once-Weekly Carfilzomib Regimen in Myeloma

August 27th 2018

A supplemental new drug application has been submitted to the FDA for a once-weekly dosing option of carfilzomib to use in combination with dexamethasone for patients with relapsed/refractory multiple myeloma.

Expert Highlights Promising Multiple Myeloma Data

August 24th 2018

Noopur Raje, MD, discusses the latest treatment advances in multiple myeloma.

FDA Grants Elotuzumab Triplet Priority Review for Myeloma

August 23rd 2018

The FDA has granted a priority review to a supplemental biologics license application for elotuzumab for use in combination with pomalidomide and low-dose dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma following 2 or more prior therapies, including lenalidomide and a proteasome inhibitor.

Advances Could Lead to Curative Strategies in Myeloma

August 21st 2018

Nikhil C. Munshi, MD, discusses the current treatment landscape of myeloma and potential next steps to further advancing care.

Dr. Holstein Discusses Triplets and Quadruplets in Myeloma

August 17th 2018

Sarah Holstein, MD, PhD, associate professor, University of Nebraska Medical Center, discusses the use of triplets and quadruplets in the treatment of patients with multiple myeloma.

Dr. Munshi on Latest Treatment Developments in Multiple Myeloma

August 16th 2018

Dr. Lonial on the OPTIMISMM and ELOQUENT-3 Trials in Myeloma

August 8th 2018

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the OPTIMISMM and ELOQUENT-3 trials in patients with relapsed/refractory multiple myeloma.

Patient-Reported Outcomes With Stem Cell Transplant Signal Progress in Myeloma

August 8th 2018

Noa Biran, MD, discusses patient-reported outcomes following autologous stem cell transplant in patients with myeloma.

Selinexor FDA Submission Completed for Multiple Myeloma

August 8th 2018

A rolling submission of an FDA new drug application has been completed for selinexor for the treatment of patients with penta-refractory multiple myeloma, according to Karyopharm Therapeutics.